--- title: "Weekly Recap | RXRX.US +10.16%, most brokers rate it buy" type: "News" locale: "en" url: "https://longbridge.com/en/news/300851395.md" description: "RXRX.US gained 10.16% this week to close at $4.12, outperforming the S&P 500 by about 10.43 percentage points. The S&P 500 fell 0.27% over the same period. The week split into two halves. Monday (28 Sep) opened lower and touched $3.665 on light volume. Tuesday (29 Sep) brought a sharp rally on 21.6m shares traded, ending at $4.03. Wednesday (30 Sep) marked the week’s high at $4.29, with 32.8m shares changing hands — the busiest session of the week. Thursday edged back to $4." datetime: "2026-10-03T07:37:28.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/300851395.md) - [en](https://longbridge.com/en/news/300851395.md) - [zh-HK](https://longbridge.com/zh-HK/news/300851395.md) generator: "portal-rs" --- # Weekly Recap | RXRX.US +10.16%, most brokers rate it buy ## The Week RXRX.US gained 10.16% this week to close at $4.12, outperforming the S&P 500 by about 10.43 percentage points. The S&P 500 fell 0.27% over the same period. The week split into two halves. Monday (28 Sep) opened lower and touched $3.665 on light volume. Tuesday (29 Sep) brought a sharp rally on 21.6m shares traded, ending at $4.03. Wednesday (30 Sep) marked the week’s high at $4.29, with 32.8m shares changing hands — the busiest session of the week. Thursday edged back to $4.07, and Friday (2 Oct) finished at $4.12, roughly matching Wednesday’s close. The weekly candle shows a solid body, with amplitude of 16.94% between the week high of $4.29 and the 60-day range low of $2.84. ## Key Events News this week was mostly sector-driven, with no company-specific filings of note. On Tuesday (29 Sep), two AI-related stories appeared in close succession. One covered the physical infrastructure race behind AI’s digital surge; the other looked at AI drugmakers riding the weight-loss wave, while bitcoin miners attracted institutional cash. Recursion, as an AI-driven drug discovery company, sat squarely within the group being repriced by the market. On Wednesday (30 Sep), a top gainers list showed the stock among the Top 10 US gainers for 29 Sep, consistent with Tuesday’s volume-driven push. Filings this week added nothing material: two routine items were dropped. The week’s story is one of risk appetite returning to AI pharma themes, with Recursion positioned at the front of that transmission. ## Analyst Ratings Eight analysts currently cover the stock: 1 buy, 2 overweight, 4 hold, and 1 no opinion. No analyst has an underweight or sell rating. The consensus rating is buy, with a consensus target price of $7.21667, about 75.16% above the current $4.12. Target prices range from $4.00 to $10.00, with the low end near spot and the high end at 2.43 times the current price, pointing to wide disagreement on upside. The stock ranks 175 out of 507 within the biotechnology industry. ## The Week Ahead Monday (5 Oct) brings final S&P Global services PMI and ISM non-manufacturing PMI. The former had a prior reading of 58.7; the latter stood at 55.4 with a forecast of 55. Tuesday (6 Oct) sees US trade balance data — prior -88.6, forecast -102 — and goods trade balance (prior -132.6). Wednesday (7 Oct) brings EIA weekly crude inventories (prior 0.922) and Cushing crude inventories (prior 0.553). These macro releases will test whether the broader risk appetite holds, and whether the AI pharma trade keeps attracting flows depends on how sector rotation plays out next week. ## In Short RXRX.US rose 10.16% this week, beat the S&P 500 by roughly 10 points, and traded with clearly higher volume — average daily turnover ran 26.2% above the median. But valuation remains stretched: negative earnings, price-to-book at 2.41x. The analyst picture leans constructive, with a buy consensus and a target 75% above spot, yet the wide target range signals real disagreement. Latest-session flow shows large-lot money tilting net seller, creating tension with the week’s volume-driven rally. The key question is whether the AI pharma theme can move from sector-level narrative to company-specific catalysts, and how next week’s macro data shape overall risk appetite. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [RXRX.US](https://longbridge.com/en/quote/RXRX.US.md) ## Related News & Research - [Could Tempus RNA License Alter The Investment Case For Recursion Pharmaceuticals (RXRX)?](https://longbridge.com/en/news/300858427.md) - [Recursion Pharmaceuticals (NASDAQ:RXRX) Director Blake Borgeson Sells 30,000 Shares of Stock](https://longbridge.com/en/news/297837155.md) - [Tesla's Q3 Delivery Beat Is Just the Start: Gene Munster Says TSLA Will ‘Crush Traditional Automakers’](https://longbridge.com/en/news/300968018.md) - [Is Oracle Stock a Good Buy While It's Trading Below $150?](https://longbridge.com/en/news/300960808.md) - [‘One for the Kids,’ Says Top Investor About SpaceX Stock](https://longbridge.com/en/news/300955937.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**